Innovent–Ollin’s bispecific antibody OLN324 delivers superior retinal drying in DME

Innovent–Ollin’s bispecific antibody OLN324 delivers superior retinal drying in DME

Ollin Biosciences and Innovent Biologics have reported positive topline results from the randomized Phase 1b JADE trial, in which OLN324 (IBI324), a next-generation VEGF/Ang2 bispecific antibody, demonstrated superior anatomical efficacy over faricimab in patients with diabetic macular edema and wet age-related macular degeneration. Conducted in over 160 patients across the United States, the head-to-head study […]